viewCardieX Ltd

AtCor Medical signs $1 million contract with international pharmaceutical company

This contract is a validation of AtCor’s technology in trials for the treatment of heart failure.

heart shape
Heart failure costs over US$30 billion annually in the U.S.

Atcor Medical Holdings Limited (ASX:ACG) has signed a $1 million contract to supply its SphygmoCor® systems and clinical trial support services to a major international pharmaceutical company.

Central arterial pressure waveform analysis, as measured by the SphygmoCor system, provides clinicians with better prognostic and diagnostic information to determine the need for and type of interventions.

New contract expected to open up more opportunities for AtCor

The international pharmaceutical company is a new client for AtCor. The clinical trial is in the treatment of heart failure and will be conducted across several European sites.

It is a phase II trial which, if successful, is expected to open a larger opportunity for AtCor.  The trial will run for 18-24 months and the majority of revenue will be recognised in FY2019.

This contract is further validation of AtCor’s core technology in large pharmaceutical trials for the treatment of heart failure and related disorders.

Heart failure is a costly disease

Heart failure is a chronic, progressive condition in which the heart muscle is unable to pump enough blood through to meet the body's needs for blood and oxygen.

In the U.S. alone, circa 5.7 million people have heart failure at a total economic cost of over US$30 billion per annum.

There is increasing interest in utilising SphygmoCor in heart failure trials and in the clinic.

This is the second heart failure trial using SphygmoCor to commence in the past 6 months and discussions are underway for additional trials.

More than 4,000 SphygmoCor systems are currently in use worldwide at major medical institutions, doctors’ offices, research institutions and in various clinical trials.

Quick facts: CardieX Ltd

Price: 0.115 AUD

Market: ASX
Market Cap: $105.99 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of CardieX Ltd named herein, including the promotion by the Company of CardieX Ltd in any Content on the Site, the Company receives from said...


CardieX Limited signs disruptive deal with Chinese medical device company Andon

CardieX Limited (ASX: CDX) CEO Craig Cooper joined Steve Darling from Proactive with news the company has entered a co-development and commercial partnership agreement with Andon. Andon is one of China’s largest manufacturers of home-use medical electronic devices. Cooper talks about the deal...

on 9/9/20

2 min read